Portfolio company CoStim Pharmaceuticals was acquired by Novartis for up to $248M.
CoStim Pharmaceuticals is focused on developing breakthrough biotechnology solutions, particularly in the field of cancer treatment through immune checkpoint modulation
CoStim Pharmaceuticals is focused on developing breakthrough biotechnology solutions, particularly in the field of cancer treatment through immune checkpoint modulation.